Shahab Khan, MD
Nephrology · Glen Burnie, MDNPI 1336182302
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,719 of the $6,070 with a category attached, or 61.3%. Amgen accounts for 78.7% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $4,651, more than ten times the $140 reported in 2019.
Across 47 payments — averaging $129.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$5K
- Novo Nordisk$328
- Akebia Therapeutics Inc$296
- Aurinia Pharma U.S., Inc.$120
- Otsuka America Pharmaceutical, Inc.$110
- Novartis$100
- plus $341 from 9 others
What the payments were for
- Speaking & faculty fees$3,71961%
- Travel & lodging$83114%
- Food & beverage$1,40123%
- Education$1202%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 8 | $4,775 |
| Novo Nordisk | 6 | $328 |
| Akebia Therapeutics Inc | 10 | $296 |
| Aurinia Pharma U.S., Inc. | 1 | $120 |
| Otsuka America Pharmaceutical, Inc. | 2 | $110 |
| Novartis | 4 | $100 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Vifor Pharma, Inc. | 3 | $65 |
| Travere Therapeutics, Inc. | 5 | $31 |
| AstraZeneca | 2 | $31 |
| Bayer | 1 | $31 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Ardelyx, Inc. | 1 | $25 |
| Fresenius USA Marketing, Inc. | 1 | $19 |
| Calliditas Therapeutics US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,070 in reported general payments places this provider in the 85th percentile of 285 nephrology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TavneosAvacopan | 12 | $196,543 |
| FarxigaDapagliflozin Propanediol | 85 | $88,488 |
| OzempicSemaglutide | 35 | $55,030 |
| KerendiaFinerenone | 28 | $42,260 |
| VeltassaPatiromer Calcium Sorbitex | 24 | $36,171 |
| Tolvaptan | 16 | $35,954 |
| LokelmaSodium Zirconium Cyclosilicate | 21 | $32,713 |
| JardianceEmpagliflozin | 24 | $26,597 |
| Clonidine | 11 | $3,227 |
| ProsolParenteral Amino Acid 20% No.1 | 21 | $3,049 |
| Calcium Acetate | 26 | $2,498 |
| Eplerenone | 32 | $1,847 |
| Potassium Citrate ErPotassium Citrate | 18 | $1,464 |
| Calcitriol | 74 | $1,363 |
| Sevelamer Carbonate | 14 | $1,183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenTavneos | $4,775 | $196,54312 claims |
| AstraZenecaFarxiga, Lokelma | $31 | $121,201106 claims |
| Novo NordiskOzempic | $328 | $55,03035 claims |
| BayerKerendia | $31 | $42,26028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 285 nephrology providers in Maryland.
Other nephrology in Glen Burnie
- Kiran SamindlaFrederick$491K
- Matthew WeirBaltimore$490K
- Chirag ParikhBaltimore$186K
- Mohamad HanounehBaltimore$174K
- Daniel BrennanBaltimore$133K
- Monika DhillonBaltimore$126K
- Duvuru GeethaBaltimore$91K
- Eli RozaHagerstown$79K
- Mohamed AttaBaltimore$65K
- Michelle EstrellaBaltimore$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.